Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.02 USD
-0.10 (-2.43%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.02 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Ironwood Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 92 | 657 | 621 | 364 | 178 |
Receivables | 129 | 115 | 114 | 122 | 117 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 1 |
Other Current Assets | 12 | 8 | 10 | 9 | 11 |
Total Current Assets | 233 | 781 | 745 | 496 | 307 |
Net Property & Equipment | 6 | 6 | 8 | 9 | 12 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 15 | 24 | 23 | 33 |
Deferred Charges | 212 | 284 | 333 | 0 | 0 |
Intangibles | 4 | 0 | 0 | 0 | 1 |
Deposits & Other Assets | 4 | 1 | 1 | 14 | 32 |
Total Assets | 471 | 1,101 | 1,127 | 559 | 403 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 0 | 1 | 1 | 5 |
Current Portion Long-Term Debt | 200 | 0 | 117 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 66 | 22 | 39 | 28 | 33 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 0 | 1 |
Total Current Liabilities | 276 | 26 | 162 | 32 | 41 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 198 | 0 | 337 | 430 | 408 |
Long-Term Debt | 300 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 28 | 406 | 4 | 14 | 25 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 817 | 448 | 521 | 497 | 496 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,355 | 1,349 | 1,543 | 1,529 | 1,479 |
Retained Earnings | -1,699 | -696 | -938 | -1,466 | -1,572 |
Other Equity | -3 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -346 | 652 | 606 | 63 | -93 |
Total Liabilities & Shareholder's Equity | 471 | 1,101 | 1,127 | 559 | 403 |
Total Common Equity | -346 | 652 | 606 | 63 | -93 |
Shares Outstanding | 156.30 | 154.00 | 162.00 | 160.60 | 157.50 |
Book Value Per Share | -2.22 | 4.24 | 3.74 | 0.39 | -0.59 |
Fiscal Year End for Ironwood Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 106 | 122 | 92 | 111 | 176 |
Receivables | 58 | 72 | 129 | 125 | 119 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 15 | 12 | 18 | 23 |
Total Current Assets | 178 | 208 | 233 | 254 | 318 |
Net Property & Equipment | 5 | 5 | 6 | 6 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 193 | 206 | 212 | 244 | 258 |
Intangibles | 3 | 3 | 4 | 4 | 4 |
Deposits & Other Assets | 4 | 3 | 4 | 4 | 4 |
Total Assets | 396 | 439 | 471 | 524 | 603 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 6 | 8 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 200 | 200 | 0 | 199 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 39 | 43 | 66 | 73 | 100 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 199 | 0 |
Total Current Liabilities | 46 | 252 | 276 | 281 | 305 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 199 | 198 | 198 | 198 | 198 |
Long-Term Debt | 425 | 275 | 300 | 325 | 400 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 35 | 28 | 31 | 31 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 717 | 769 | 817 | 850 | 950 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,382 | 1,373 | 1,355 | 1,375 | 1,367 |
Retained Earnings | -1,704 | -1,703 | -1,699 | -1,698 | -1,713 |
Other Equity | 0 | -1 | -3 | -3 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -322 | -331 | -346 | -326 | -347 |
Total Liabilities & Shareholder's Equity | 396 | 439 | 471 | 524 | 603 |
Total Common Equity | -322 | -331 | -346 | -326 | -347 |
Shares Outstanding | 159.70 | 156.50 | 156.30 | 156.10 | 156.00 |
Book Value Per Share | -2.01 | -2.11 | -2.22 | -2.09 | -2.22 |